| pubmed-article:16225177 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16225177 | lifeskim:mentions | umls-concept:C1882071 | lld:lifeskim |
| pubmed-article:16225177 | lifeskim:mentions | umls-concept:C0521390 | lld:lifeskim |
| pubmed-article:16225177 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:16225177 | lifeskim:mentions | umls-concept:C1121410 | lld:lifeskim |
| pubmed-article:16225177 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:16225177 | pubmed:dateCreated | 2005-10-17 | lld:pubmed |
| pubmed-article:16225177 | pubmed:abstractText | Controversial data was published about the sodium channel-blocking effect of the endogenous pentapeptide QYNAD, which is elevated in patients with multiple sclerosis and Guillain-Barré-syndrome. In some experiments with single cells and nerve preparations QYNAD inhibited sodium currents to the same extent as the known sodium channel blocker lidocaine whereas in other laboratory testing QYNAD failed to show any effect at all. | lld:pubmed |
| pubmed-article:16225177 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16225177 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16225177 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16225177 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16225177 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16225177 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16225177 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16225177 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16225177 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16225177 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16225177 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:16225177 | pubmed:issn | 0317-1671 | lld:pubmed |
| pubmed-article:16225177 | pubmed:author | pubmed-author:OttoFF | lld:pubmed |
| pubmed-article:16225177 | pubmed:author | pubmed-author:HartungH PHP | lld:pubmed |
| pubmed-article:16225177 | pubmed:author | pubmed-author:SieblerMM | lld:pubmed |
| pubmed-article:16225177 | pubmed:author | pubmed-author:GörtzPP | lld:pubmed |
| pubmed-article:16225177 | pubmed:author | pubmed-author:KieseierB CBC | lld:pubmed |
| pubmed-article:16225177 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16225177 | pubmed:volume | 32 | lld:pubmed |
| pubmed-article:16225177 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16225177 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16225177 | pubmed:pagination | 344-8 | lld:pubmed |
| pubmed-article:16225177 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16225177 | pubmed:meshHeading | pubmed-meshheading:16225177... | lld:pubmed |
| pubmed-article:16225177 | pubmed:meshHeading | pubmed-meshheading:16225177... | lld:pubmed |
| pubmed-article:16225177 | pubmed:meshHeading | pubmed-meshheading:16225177... | lld:pubmed |
| pubmed-article:16225177 | pubmed:meshHeading | pubmed-meshheading:16225177... | lld:pubmed |
| pubmed-article:16225177 | pubmed:meshHeading | pubmed-meshheading:16225177... | lld:pubmed |
| pubmed-article:16225177 | pubmed:meshHeading | pubmed-meshheading:16225177... | lld:pubmed |
| pubmed-article:16225177 | pubmed:meshHeading | pubmed-meshheading:16225177... | lld:pubmed |
| pubmed-article:16225177 | pubmed:meshHeading | pubmed-meshheading:16225177... | lld:pubmed |
| pubmed-article:16225177 | pubmed:meshHeading | pubmed-meshheading:16225177... | lld:pubmed |
| pubmed-article:16225177 | pubmed:meshHeading | pubmed-meshheading:16225177... | lld:pubmed |
| pubmed-article:16225177 | pubmed:meshHeading | pubmed-meshheading:16225177... | lld:pubmed |
| pubmed-article:16225177 | pubmed:meshHeading | pubmed-meshheading:16225177... | lld:pubmed |
| pubmed-article:16225177 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16225177 | pubmed:articleTitle | The pentapeptide QYNAD does not inhibit neuronal network activity. | lld:pubmed |
| pubmed-article:16225177 | pubmed:affiliation | Department of Neurology, Heinrich-Heine-University Düisseldorf, Germany. | lld:pubmed |
| pubmed-article:16225177 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16225177 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
